AR050521A1 - Combinaciones para el tratamiento de enfermedades que implican una proliferacion celular - Google Patents
Combinaciones para el tratamiento de enfermedades que implican una proliferacion celularInfo
- Publication number
- AR050521A1 AR050521A1 ARP050103380A ARP050103380A AR050521A1 AR 050521 A1 AR050521 A1 AR 050521A1 AR P050103380 A ARP050103380 A AR P050103380A AR P050103380 A ARP050103380 A AR P050103380A AR 050521 A1 AR050521 A1 AR 050521A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- inhibitors
- optionally
- aryl
- synthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a una composicion farmacéutica para el tratamiento de enfermedades que implican una proliferacion celular. También se refiere a un método para el tratamiento de dichas enfermedades, que comprende la co-administracion de un compuesto de formula (1), en donde los grupos L, R1, R2, R3, R4 y R5 tienen los significados dados en la reivindicaciones y en la parte descriptiva, opcionalmente en forma de sus tautomeros, racematos, enantiomeros, diastereoisomeros y sus mezclas y, opcionalmente, en forma de sus sales por adicion de ácidos, solvatos, hidratos, polimorfos, derivados fisiologicamente funcionales o profármacos farmacologicamente aceptables, y una cantidad eficaz de un compuesto activo 2 y/o co-tratamiento con terapia de radiacion, en una relacion que proporciona un efecto aditivo y sinérgico, y al uso combinado de un compuesto de formula (1) y de una cantidad eficaz de un compuesto activo 2 y/o radioterapia, para la fabricacion de preparaciones de combinacion farmacéuticas correspondientes. Combinacion farmacéutica y kit de preparacion de combinacion farmacéutica. Reivindicacion 1: Una combinacion farmacéutica, que comprende cantidad eficaces de: i) un compuesto de formula (1), en donde: R1, R2, que pueden ser idénticos o diferentes, significan hidrogeno o alquilo C1-6 opcionalmente sustituido; o R1 y R2 juntos significan un puente alquilo de 2 a 5 miembros que puede contener 1 a 2 heteroátomos; R3 significa hidrogeno o un grupo seleccionado entre alquilo C1-12, alquenilo C2-12, alquinilo C2-12 o arilo C6-14 opcionalmente sustituido; o un grupo seleccionado entre cicloalquilo C3-12, cicloalquenilo C3-12, policicloalquilo C7-12, policicloalquenilo C7-12, espirocicloalquilo C5-12, heterocicloalquilo C3-12, opcionalmente sustituido y/o puenteado, que contiene 1 a 2 heteroátomos, y heterocicloalquenilo C3-12 que contiene 1 a 2 heteroátomos; o R1 y R3, o R2 y R3 juntos significan un puente alquilo C3-4 saturado o insaturado que puede contener 1 heteroátomo; R4 significa un grupo seleccionado entre hidrogeno, -CN, hidroxi, -NR6R7 y halogeno; o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquiloxi C1-5, alqueniloxi C2-5, alquiniloxi C2-5, alquiltio C1-6, alquilsulfoxo C1-6 y alquilsulfonilo C1-6, opcionalmente sustituido; L significa un enlazador seleccionado entre alquilo C2-10, alquenilo C2-10, arilo C6-14; -alquilC2-4-ariloC6-14, -arilC6-14-alquiloC1-4 opcionalmente sustituido, cicloalquilo C3-12 opcionalmente puenteado y heteroarilo que contiene 1 a 2 átomos de nitrogeno; n significa 0 o 1; m significa 1 o 2; R5 significa un grupo seleccionado entre morfolinilo, piperidinilo, piperazinilo, piperazinilcarbonilo, pirrolidinilo, tropenilo, R8-dicetometilpiperazinilo, sulfoxomorfolinilo, sulfonilmorfolinilo, tiomorfolinilo, -NR8R9 y azacicloheptilo opcionalmente sustituido; R6, R7, que pueden ser idénticos o diferentes, significan hidrogeno o alquilo C1-4; y R8, R9 significan sustituyentes hidrogeno no sustituidos en R5 que pueden ser idénticos o diferentes, significan hidrogeno o un grupo seleccionado entre alquilo C1-6, -alquilC1-4-cicloalquilo-C3-10, cicloalquilo C3-10, arilo C6-14, -alquilC1-4-ariloC6-14, piranilo, piridinilo, pirimidinilo, alquiloxiC1-4-carbonilo, arilC6-14-carbonilo, alquilC1-4-carbonilo, arilC6-14-metiloxicarbonilo, arilC6-14-sulfonilo, alquilC1-4-sulfonilo y -arilC6-14-alquilC1-4-sulfonilo; opcionalmente en forma de sus tautomeros racematos, enantiomeros, diastereoisomeros y sus mezclas y opcionalmente en forma de sus sales por adicion de ácidos, solvatos, hidratos, polimorfos, derivados fisiologicamente funcionales o profármacos farmacologicamente aceptables; y ii) al menos un agente 2 quimioterapéutico o terapéutico que se produce en la naturaleza, semi-sintético o sintético adicional; opcionalmente en combinacion con uno o más excipientes farmacéuticamente aceptables, y opcionalmente destinado a un co-tratamiento con radioterapia o radio-inmunoterapia en forma de un preparado combinado para uso simultáneo, separado o secuencial en el tratamiento de enfermedades que implican una proliferacion celular, migracion o apoptosis de células cancerígenas. Reivindicacion 3: Una composicion farmacéutica de acuerdo con la reivindicacion 1 o 2, en donde el agente 2 quimioterapéutico o terapéutico que se produce en la naturaleza, semi-sintético o sintético adicional se selecciona del grupo que consiste en antagonistas del receptor de VEGF de moléculas pequenas sintéticos, antagonistas del receptor del factor de crecimiento de moléculas pequenas, inhibidores del receptor de EGF y/o del receptor de VEGF y/o de receptores de integrina o cuales quiera otros receptores de la proteína tirosina quinasa que no se clasifican bajo las moléculas pequenas sintéticas, inhibidores dirigidos al receptor de EGF y/o al receptor de VEGF y/o a receptores de integrina o cualquiera otros receptores de la proteína de tirosina quinasa, que son proteínas de fusion, compuestos que interactuan con ácidos nucleicos y que se clasifican como agentes alquilantes o compuestos de platino, compuestos que interactuan con ácidos nucleicos y que se clasifican como antraciclinas, como intercaladores de ADN o como agentes reticulantes de ADN, incluidos compuestos de union de ranura pequena de ADN, anti-metabolitos, antibioticos del tipo bleomicina que se producen en la naturaleza, semi-sintéticos o sintéticos, inhibidores de enzimas transcriptoras de ADN y, especialmente, los inhibidores de topoisomerasa I o topoisomerasa II, agentes modificadores de cromatina, inhibidores de la mitosis, agentes anti-mitoticos, inhibidores del ciclo celular, inhibidores de proteasoma, enzimas, hormonas, antagonistas de hormonas, inhibidores de hormonas, inhibidores de la biosíntesis de esteroides, esteroides, citoquinas, citotoxinas selectivas de la hipoxia, inhibidores de citoquinas, linfoquinas, anticuerpos dirigidos contra citoquinas, agentes de induccion de la tolerancia oral y parenteral, agentes de soporte, sensibilizadores y protectores de la radiacion química, fármacos fotoquímicamente activados, polinucleotidos u oligonucléotidos sintéticos, fármacos antiinflamatorios no esteroides, opcionalmente modificados o conjugados, antibioticos citotoxicos, anticuerpos dirigidos contra factores de crecimiento o sus receptores, anticuerpos dirigidos contra las moléculas de la superficie de células cancerígenas, inhibidores de metaloproteinasas, metales, inhibidores de oncogenes, inhibidores de la transcripcion génica o de la traduccion de ARN o de la expresion de proteínas, complejos de elementos de tierras raras, compuestos que reducen el transporte de hialuronano mediado por uno o más transportadores ABC y agentes foto-quimioterapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04019361 | 2004-08-14 | ||
EP04019448 | 2004-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050521A1 true AR050521A1 (es) | 2006-11-01 |
Family
ID=35241347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103380A AR050521A1 (es) | 2004-08-14 | 2005-08-12 | Combinaciones para el tratamiento de enfermedades que implican una proliferacion celular |
Country Status (26)
Country | Link |
---|---|
US (3) | US20060058311A1 (es) |
EP (2) | EP2275107B1 (es) |
JP (1) | JP5043660B2 (es) |
KR (1) | KR101258426B1 (es) |
CN (1) | CN101039673B (es) |
AR (1) | AR050521A1 (es) |
AT (1) | ATE512663T1 (es) |
AU (1) | AU2005274384B2 (es) |
BR (1) | BRPI0514357A (es) |
CA (1) | CA2576269C (es) |
CY (1) | CY1112200T1 (es) |
DK (2) | DK1827441T3 (es) |
ES (1) | ES2602465T3 (es) |
HR (1) | HRP20110578T1 (es) |
HU (1) | HUE032436T2 (es) |
IL (1) | IL181305A (es) |
ME (1) | ME01209B (es) |
MX (2) | MX2007001853A (es) |
NZ (1) | NZ553729A (es) |
PL (2) | PL2275107T3 (es) |
PT (1) | PT1827441E (es) |
RS (1) | RS51807B (es) |
RU (2) | RU2407532C9 (es) |
SI (1) | SI1827441T1 (es) |
TW (2) | TW201201810A (es) |
WO (1) | WO2006018182A1 (es) |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100709909B1 (ko) * | 1999-06-21 | 2007-04-24 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법 |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10349113A1 (de) * | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
CZ2004964A3 (cs) * | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
PT1848414E (pt) | 2005-02-03 | 2011-05-25 | Gen Hospital Corp | M?todo para tratamento de cancro resistente a gefitinib |
AR057854A1 (es) | 2005-11-04 | 2007-12-19 | Wyeth Corp | Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida |
US8404697B2 (en) * | 2005-11-11 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
ES2412879T3 (es) * | 2005-11-11 | 2013-07-12 | Boehringer Ingelheim International Gmbh | Tratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2 |
CA2639936C (en) * | 2006-01-26 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
RU2426542C2 (ru) * | 2006-05-26 | 2011-08-20 | Селджин Корпорейшн | Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
NZ576065A (en) * | 2006-09-18 | 2011-12-22 | Boehringer Ingelheim Int | Method for treating cancer harboring egfr mutations |
JP5513118B2 (ja) * | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ,エルエルシー | ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用 |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
DE602007012473D1 (de) | 2006-12-14 | 2011-03-24 | Vertex Pharma | Als proteinkinaseinhibitoren geeignete verbindungen |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
US20100310661A1 (en) * | 2007-07-16 | 2010-12-09 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
CA2695406A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
WO2009023846A2 (en) * | 2007-08-15 | 2009-02-19 | The Research Foundation Of State University Of New York | Methods for heat shock protein dependent cancer treatment |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
AU2016225895B2 (en) * | 2007-10-17 | 2018-02-08 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof |
EP2244714A4 (en) * | 2008-02-08 | 2012-06-06 | Poniard Pharmaceuticals Inc | USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER |
EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
PE20100252A1 (es) * | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
PL2293795T3 (pl) * | 2008-06-06 | 2016-01-29 | Boehringer Ingelheim Int | Kombinacja farmaceutyczna |
US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
AU2015227503B2 (en) * | 2008-06-06 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
EP2299987B1 (en) * | 2008-06-06 | 2018-02-21 | Boehringer Ingelheim International GmbH | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
KR20180128078A (ko) | 2008-06-17 | 2018-11-30 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
KR20110039278A (ko) * | 2008-06-23 | 2011-04-15 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제 |
KR20140069340A (ko) | 2008-08-04 | 2014-06-09 | 와이어쓰 엘엘씨 | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 |
JP2012509878A (ja) * | 2008-11-21 | 2012-04-26 | アイシス ファーマシューティカルズ, インコーポレーテッド | ドセタキセルおよびアンチセンスオリゴヌクレオチドを含む、抗腫瘍併用療法 |
WO2010064422A1 (ja) * | 2008-12-02 | 2010-06-10 | 静岡県公立大学法人 | ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法 |
CN102369010A (zh) | 2009-04-06 | 2012-03-07 | 惠氏有限责任公司 | 用于乳腺癌的利用奈拉替尼的治疗方案 |
KR101224468B1 (ko) * | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
ES2543280T3 (es) * | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
MY173795A (en) | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
KR20120123513A (ko) * | 2010-02-03 | 2012-11-08 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제자에 대한 민감성 예측 바이오마커로서 lkb1 돌연변이의 동정 |
JP5841548B2 (ja) * | 2010-02-17 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン、その製造方法及び使用 |
BR122014024883A2 (pt) | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
WO2011143657A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
US20110280862A1 (en) * | 2010-05-14 | 2011-11-17 | The University Of Hong Kong | Gep and drug transporter regulation, cancer therapy and prognosis |
SG186885A1 (en) | 2010-06-04 | 2013-02-28 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
ES2655115T3 (es) | 2010-08-26 | 2018-02-16 | Boehringer Ingelheim International Gmbh | Procedimientos de administración de un inhibidor de EGFR |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
CN103384672B (zh) | 2011-02-25 | 2016-09-28 | 武田药品工业株式会社 | N-取代的噁嗪并喋啶和噁嗪并喋啶酮 |
SI2705029T1 (sl) | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S.A. | Nove spojine kot modulatori protein-kinaz |
US20130131069A1 (en) * | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
EP2838879A1 (en) | 2012-04-20 | 2015-02-25 | Concert Pharmaceuticals Inc. | Deuterated rigosertib |
MY169987A (en) | 2012-07-04 | 2019-06-19 | Rhizen Pharmaceuticals Sa | Selective pi3k delta inhibitors |
EP2875020B1 (en) | 2012-07-19 | 2017-09-06 | Boehringer Ingelheim International GmbH | Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one |
EP2882496B1 (en) * | 2012-08-13 | 2019-10-09 | The Rockefeller University | Treatment and diagnosis of melanoma |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US9643950B2 (en) | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
ES2944478T3 (es) | 2013-04-17 | 2023-06-21 | Signal Pharm Llc | 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme |
NZ629411A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
CN105324381A (zh) | 2013-04-17 | 2016-02-10 | 西格诺药品有限公司 | 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法 |
AU2014254058B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer |
CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
MX2015014455A (es) | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. |
EP2986322A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
EA201600133A1 (ru) * | 2013-07-26 | 2016-07-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Воласертиб в комбинации с децитабином для лечения острого миелоидного лейкоза и миелодиспластического синдрома |
WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
US20150031643A1 (en) * | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
CN105849110B (zh) | 2013-11-08 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
US9371321B2 (en) | 2014-01-09 | 2016-06-21 | Astrazeneca Ab | Azaindole derivatives |
EP3099696A4 (en) | 2014-01-31 | 2017-07-05 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
JP2017512186A (ja) * | 2014-01-31 | 2017-05-18 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジヒドロプテリジノン誘導体およびその使用 |
JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアゼパン誘導体の使用 |
WO2015117053A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
WO2016022902A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
PL3214081T3 (pl) | 2014-10-30 | 2021-04-06 | Kangpu Biopharmaceuticals, Ltd. | Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie |
CN106279173A (zh) * | 2015-05-29 | 2017-01-04 | 华东理工大学 | 蝶啶酮衍生物作为egfr抑制剂的应用 |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10881668B2 (en) | 2015-09-11 | 2021-01-05 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
AU2016361478B2 (en) | 2015-11-25 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
CN106831765B (zh) * | 2016-12-28 | 2018-12-14 | 郑州大学 | 2-(2,6-二氰基苯基)咪唑并[1,2-α]吡啶类化合物及其制备方法 |
PL3590924T3 (pl) | 2017-02-28 | 2022-01-24 | Kangpu Biopharmaceuticals, Ltd. | Nowa pochodna izoindoliny oraz jej kompozycja farmaceutyczna i zastosowanie |
CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
CN109776788B (zh) * | 2017-11-14 | 2021-07-30 | 博瑞生物医药(苏州)股份有限公司 | 叶酸受体靶向多臂偶联物 |
JP2021511352A (ja) | 2018-01-25 | 2021-05-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性骨髄性白血病の併用処置 |
AU2019257651B2 (en) | 2018-04-24 | 2023-05-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
WO2020114482A1 (zh) | 2018-12-06 | 2020-06-11 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
CN110156700A (zh) * | 2019-06-05 | 2019-08-23 | 鲁南制药集团股份有限公司 | 吉非替尼与水杨酸共晶体 |
MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8303657A (nl) | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
DE3537761A1 (de) | 1985-10-24 | 1987-04-30 | Bayer Ag | Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure |
JPH0276860A (ja) | 1987-10-05 | 1990-03-16 | Toyo Jozo Co Ltd | 6−置換アルコキシ−2−オキソ−1,2−ジヒドロキノキサリン誘導体 |
DE68908786T2 (de) | 1988-06-16 | 1994-03-17 | Smith Kline French Lab | Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. |
FR2645152B1 (fr) | 1989-03-30 | 1991-05-31 | Lipha | 3h-pteridinones-4, procedes de preparation et medicaments les contenant |
US5043270A (en) * | 1989-03-31 | 1991-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | Intronic overexpression vectors |
CA2029651C (en) | 1989-11-17 | 2000-06-06 | David D. Davey | Tricyclic pteridinones and a process for their preparation |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
TW274550B (es) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
GB9418499D0 (en) | 1994-09-14 | 1994-11-02 | Ciba Geigy Ag | Process for producing n-methylated organic pigments |
CO4410190A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
ES2154825T3 (es) | 1995-05-19 | 2001-04-16 | Novartis Ag | Procedimiento para la hidrogenacion catalitica de nitro compuestos aromaticos. |
US5698556A (en) | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
EA001881B1 (ru) | 1996-09-23 | 2001-10-22 | Эли Лилли Энд Компани | Форма d дигидрата оланзапина |
EE200100085A (et) | 1998-08-11 | 2002-08-15 | Pfizer Products Inc. | Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid |
WO2000043369A1 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
JP2003509425A (ja) | 1999-09-15 | 2003-03-11 | ワーナー−ランバート・カンパニー | キナーゼ阻害剤としてのプテリジノン |
UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
AP2002002643A0 (en) | 2000-03-06 | 2002-12-31 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
DE10018783A1 (de) | 2000-04-15 | 2001-10-25 | Fresenius Kabi De Gmbh | Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt |
US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
DE10058119A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Pepinotan-Kit |
EP1353693B1 (en) * | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
EP1427730B1 (de) | 2001-09-04 | 2006-07-12 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
WO2003051344A1 (en) | 2001-12-14 | 2003-06-26 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation_using a non-polypeptide camp level modulator |
CN1649853A (zh) | 2002-05-03 | 2005-08-03 | 舍林股份公司 | 噻唑烷酮类化合物、其制备方法以及作为药物的应用 |
PE20040701A1 (es) * | 2002-07-23 | 2004-11-30 | Boehringer Ingelheim Pharma | Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos |
FR2843114B1 (fr) | 2002-08-01 | 2004-09-10 | Poudres & Explosifs Ste Nale | Procede de monomethylation d'heterocycles azotes |
AU2003265348B2 (en) | 2002-08-08 | 2007-08-16 | Smithkline Beecham Corporation | Thiophene compounds |
CN100537570C (zh) | 2003-02-26 | 2009-09-09 | 贝林格尔英格海姆法玛两合公司 | 二氢蝶啶酮、其制法及作为药物制剂的用途 |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
CA2517010C (en) | 2003-03-26 | 2013-09-24 | Wyeth | Plasmid dna in combination with recombinant vsv for use in prime-boost immunization regimens |
WO2004093848A2 (en) | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
DE102004002557A1 (de) | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
WO2005067935A1 (de) | 2004-01-17 | 2005-07-28 | Boehringer Ingelheim International Gmbh | Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
DE102004034623A1 (de) | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
EP1632493A1 (de) | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
WO2006021547A1 (de) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
EP1784406A1 (de) | 2004-08-27 | 2007-05-16 | Boehringer Ingelheim International GmbH | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
EP1915155A1 (en) | 2005-08-03 | 2008-04-30 | Boehringer Ingelheim International GmbH | Dihydropteridinones in the treatment of respiratory diseases |
ES2412879T3 (es) | 2005-11-11 | 2013-07-12 | Boehringer Ingelheim International Gmbh | Tratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2 |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
WO2007102767A1 (en) | 2006-03-07 | 2007-09-13 | Astrazeneca Ab | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them |
JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
CA2695406A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
JP4642085B2 (ja) | 2008-01-17 | 2011-03-02 | 日本下水道事業団 | 予測健全度を利用した施設管理および更新計画システム |
EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
JP5841548B2 (ja) | 2010-02-17 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン、その製造方法及び使用 |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US20130131069A1 (en) | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
-
2005
- 2005-07-26 US US11/189,540 patent/US20060058311A1/en not_active Abandoned
- 2005-08-09 RU RU2007109108/15A patent/RU2407532C9/ru not_active IP Right Cessation
- 2005-08-09 EP EP10184338.1A patent/EP2275107B1/en active Active
- 2005-08-09 RS RS20110302A patent/RS51807B/en unknown
- 2005-08-09 PT PT05770228T patent/PT1827441E/pt unknown
- 2005-08-09 BR BRPI0514357-8A patent/BRPI0514357A/pt active Search and Examination
- 2005-08-09 ES ES10184338.1T patent/ES2602465T3/es active Active
- 2005-08-09 DK DK05770228.4T patent/DK1827441T3/da active
- 2005-08-09 JP JP2007526349A patent/JP5043660B2/ja active Active
- 2005-08-09 HU HUE10184338A patent/HUE032436T2/en unknown
- 2005-08-09 DK DK10184338.1T patent/DK2275107T3/en active
- 2005-08-09 CA CA2576269A patent/CA2576269C/en not_active Expired - Fee Related
- 2005-08-09 SI SI200531347T patent/SI1827441T1/sl unknown
- 2005-08-09 PL PL10184338T patent/PL2275107T3/pl unknown
- 2005-08-09 PL PL05770228T patent/PL1827441T3/pl unknown
- 2005-08-09 MX MX2007001853A patent/MX2007001853A/es active IP Right Grant
- 2005-08-09 WO PCT/EP2005/008623 patent/WO2006018182A1/en active Application Filing
- 2005-08-09 CN CN2005800352724A patent/CN101039673B/zh not_active Expired - Fee Related
- 2005-08-09 NZ NZ553729A patent/NZ553729A/en not_active IP Right Cessation
- 2005-08-09 EP EP05770228A patent/EP1827441B1/en active Active
- 2005-08-09 AT AT05770228T patent/ATE512663T1/de active
- 2005-08-09 ME MEP-2011-124A patent/ME01209B/me unknown
- 2005-08-09 AU AU2005274384A patent/AU2005274384B2/en not_active Ceased
- 2005-08-09 KR KR1020077005955A patent/KR101258426B1/ko not_active IP Right Cessation
- 2005-08-12 AR ARP050103380A patent/AR050521A1/es unknown
- 2005-08-12 TW TW100137048A patent/TW201201810A/zh unknown
- 2005-08-12 TW TW094127595A patent/TWI361071B/zh active
-
2007
- 2007-02-13 IL IL181305A patent/IL181305A/en not_active IP Right Cessation
- 2007-02-14 MX MX2012003352A patent/MX340965B/es unknown
-
2009
- 2009-05-07 US US12/437,280 patent/US8143247B2/en active Active
-
2010
- 2010-09-01 RU RU2010136326/15A patent/RU2521394C2/ru not_active IP Right Cessation
-
2011
- 2011-08-03 HR HR20110578T patent/HRP20110578T1/hr unknown
- 2011-09-13 CY CY20111100877T patent/CY1112200T1/el unknown
-
2012
- 2012-01-03 US US13/342,507 patent/US8591895B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050521A1 (es) | Combinaciones para el tratamiento de enfermedades que implican una proliferacion celular | |
JP7274450B2 (ja) | 癌を処置するための医薬組合せ | |
ES2913470T3 (es) | Métodos de tratamiento de cáncer de mama AR+ | |
EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
ES2784793T3 (es) | Sistema de suministro in vivo optimizado con agentes endosomolíticos para conjugados de ácidos nucleicos | |
ES2660263T3 (es) | Combinación de compuesto inhibidor de AKT y abiraterona para su uso en tratamientos terapéuticos | |
US20090054415A1 (en) | Combinations, methods and compositions for treating cancer | |
JP2017528524A5 (es) | ||
ES2705529T3 (es) | Tratamiento combinatorio del cáncer | |
JP2023504230A (ja) | Prmt5阻害剤の組合せ医薬 | |
KR20080028919A (ko) | 티에노피리미딘 및 티에노피리딘 키나제 조절제를 사용한flt3 키나제의 상승적 조절 | |
ES2528485T3 (es) | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
CL2009001160A1 (es) | Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica. | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
AR045762A1 (es) | Derivados de quinazolina | |
AU2014344789B2 (en) | Pharmaceutical combinations for the treatment of cancer | |
ES2688809T3 (es) | Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer | |
AR049136A1 (es) | Composicion y metodo con irinotecan (cpt-11) y un inhibidor del egfr,como erlotinib | |
JP2014065696A5 (es) | ||
JP2017530983A (ja) | 相乗的オーリスタチン組合せ | |
RU2019119320A (ru) | Терапия метастатического уротелиального рака с использованием конъюгата антитело-лекарственное средство сацитузумаба говитекана (immu-132) | |
TW201642859A (zh) | Mdm2抑制劑及btk抑制劑之倂用治療法 | |
KR20220034862A (ko) | 톨-유사 수용체 효능제로서의 이미다조[4,5-c]피리딘 유도체 | |
CL2008002316A1 (es) | Compuestos heterociclicos nitrogenados que contienen fenilendiamina sustituida, inhibidores de la interaccion entre mdm2 y p53; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |